Minimal Residual Disease Market size is anticipated to reach USD 20 billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of minimal residual disease was over USD 10 billion. One of the predominant factors propelling the minimal residual disease (MRD) revenue share is the relentless advancement in diagnostic technologies specifically designed for precise and sensitive detection of residual cancer cells.
Recent years have seen significant growth in SGD testing use, largely because of the Genomics England 100,000 Genomes Project. As the understanding of cancer biology deepens, there is an increasing demand for sophisticated tools capable of identifying minimal residual disease with heightened accuracy, thereby influencing treatment decisions and patient outcomes. Continuous innovations in diagnostic methodologies, notably the integration of next-generation sequencing (NGS), liquid biopsy techniques, and highly sensitive imaging technologies, have significantly enhanced the capabilities of MRD detection.
In addition, the increasing prevalence of cancer ailment worldwide will also significantly propel the minimal residual disease market growth rate. In fact, globally people 69 years of age and younger, who were in the prime of their lives, accounted for around 57% of new cancer cases and 47% of cancer deaths. By providing more accurate and reliable information about the presence of minimal residual disease, clinicians can tailor treatment plans more precisely, leading to improved patient outcomes and a higher likelihood of successful long-term remission.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
8% |
|
Base Year Market Size (2023) |
USD 10 Billion |
|
Forecast Year Market Size (2036) |
USD 20 Billion |
|
Regional Scope |
|
Type (Molecular, Immunophenotypic)
The molecular segment in the minimal residual disease market is estimated to gain the largest revenue share of 60% in the year 2036. One of the primary growth drivers for the molecular segment is the continuous advancement in sensitivity and specificity of molecular MRD techniques. MRD assays must have broad applicability, precision, dependability, and high sensitivity (≥10−4). Additionally, the genetic target for molecular MRD analysis should be sensitive, and stable across time (i.e., present at both diagnosis and relapse) to reflect the dynamics of the malignant clone during therapy, and typical of the disease for all leukemic clones.
Collaborative efforts between research institutions, pharmaceutical companies, and healthcare providers continually validate the efficacy of molecular MRD techniques, fostering confidence in their clinical utility. A multicenter trial involving European institutions, published in Blood, validated the use of ASO-PCR in monitoring MRD in acute promyelocytic leukemia (APL).
Technology (PCR, Flow Cytometry, NGS)
The flow cytometry segment will hold almost 56% of the revenue share on account of the increasing and pervasive use of flow cytometry to detect cancer cells as it is the most powerful tool available worldwide. Moreover, according to laboratory studies in clinical samples, assays utilizing polymerase chain reaction or flow cytometry can identify a single ALL cell out of 10,000–100,000 normal cells. For MRD monitoring, leukemia immunophenotypes, and antigen-receptor gene rearrangements characterize the great majority of patients; presently, around half of the cases exhibit appropriate gene fusions. Therefore, this technology of MRD will help to boost the market gains.
A useful technique for phenotyping microbial cells is flow cytometry, which makes it possible to quickly analyze and characterize a variety of microbial populations. It can recognize and categorize various bacterial species according to their phenotypic traits. Researchers can assess the number of various microbial species or cell types present in a sample using fluorescent dyes or antibodies that target specific microbial markers. This information can be used to gain insights into population dynamics and the composition of microbial communities.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
End User |
|
|
Technology |
|
|
Test Type |
|
|
Application |
|
North American Market Statistics
The minimal residual disease market in the North American region is projected to hold the largest revenue share of 42% by the end of 2036. This heightened expansion will be attributed to the rising cases of different kinds of cancers in North America. As cancer cases are on the rise in this region, North America is highly inclining towards minimal residual disease techniques. It is anticipated that there will be 611,720 cancer deaths and 2,001,140 new cancer cases in the US in 2024. Lung cancer continues to be the leading cause of cancer-related mortality in both sexes, with prostate and breast cancers being diagnosed more frequently in men and women, respectively.
The United States and Canada have comparable patterns in the incidence of cancer, which can be attributed to the commonality of risk factors for the disease. Cancers linked to infections have a low incidence, whereas cancers linked to "westernization" of lifestyle have a high incidence. For instance, colorectal cancer incidence is greatest in Northern America among all regions of the world. Therefore, the advancement of the market can be noticed here the most.
APAC Market Analysis
The minimal residual disease market in the APAC region is projected to hold the second-largest share during the forecast period. This relentless advancement will be noticed because of rising investment in the field of screening and the existence of supportive compensation policies. For instance, China's outbound stock of foreign direct investment (FDI) rose 93 times between 2000 and 2021, whereas global FDI stocks expanded by 5.6 times during the same period. The stock of inward Chinese FDI increased dramatically in nations including Australia, Canada, and the United States; inflows peaked in 2016–2017.
Again, plans for a ¥ 10 trillion (USD 75 billion) national endowment fund were presented by Japan in 2021. Its designers claim that fostering innovation and enhancing governance are the goals. All these investments and reimbursement policies in the countries of the APAC region on R&D and the field of screening will further enlarge the market revenue.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?